Moclobemide in social phobia: A controlled dose-response trial

Russell Noyes, Georges Moroz, Jonathan R T Davidson, Michael R. Liebowitz, Arnold Davidson, Judith Siegel, Jon Bell, John W. Cain, Sharon M. Curlik, Thomas A. Kent, R. Bruce Lydiard, Alan G. Mallinger, Mark H. Pollack, Mark Rapaport, Steven A. Rasmussen, Dawson Hedges, Edward Schweizer, Eberhard H. Uhlenhuth

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Although the monoamine oxidase inhibitor phenelzine has proven efficacious in social phobia, the risk of hypertensive crises has reduced its acceptability. The reversible monoamine oxidase inhibitor moclobemide has less potential for such reactions, but; its efficacy in this disorder remains unproven. A double-blind, placebo-controlled study was undertaken to assess the efficacy and safety of fixed doses of moclobemide. After a 1-week placebo run-in, subjects with social phobia were randomly assigned to placebo or one of five doses (75 mg, 150 mg, 300 mg, 600 mg, or 900 mg daily) of moclobemide for 12 weeks. Although a trend toward greater efficacy of higher doses of moclobemide was observed at 8 weeks, no differences in response to various doses of the drug and placebo were observed at 12 weeks. At 12 weeks, 35% of subjects on 900 mg of moclobemide and 33% of those on placebo were at least much improved. Moclobemide was well tolerated, insomnia being the only dose-related adverse event observed with the drug. In this dose-response trial, moclobemide did not demonstrate efficacy at; 12 weeks. Some other controlled studies have found moclobemide and brofaromine, another reversible monoamine oxidase inhibitor, efficacious in social phobia. Possible reasons for inconsistent findings are discussed.

Original languageEnglish (US)
Pages (from-to)247-254
Number of pages8
JournalJournal of Clinical Psychopharmacology
Volume17
Issue number4
DOIs
StatePublished - Aug 1997

Fingerprint

Moclobemide
Placebos
Monoamine Oxidase Inhibitors
Phenelzine
Social Phobia
Sleep Initiation and Maintenance Disorders
Pharmaceutical Preparations
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Noyes, R., Moroz, G., Davidson, J. R. T., Liebowitz, M. R., Davidson, A., Siegel, J., ... Uhlenhuth, E. H. (1997). Moclobemide in social phobia: A controlled dose-response trial. Journal of Clinical Psychopharmacology, 17(4), 247-254. https://doi.org/10.1097/00004714-199708000-00002

Moclobemide in social phobia : A controlled dose-response trial. / Noyes, Russell; Moroz, Georges; Davidson, Jonathan R T; Liebowitz, Michael R.; Davidson, Arnold; Siegel, Judith; Bell, Jon; Cain, John W.; Curlik, Sharon M.; Kent, Thomas A.; Bruce Lydiard, R.; Mallinger, Alan G.; Pollack, Mark H.; Rapaport, Mark; Rasmussen, Steven A.; Hedges, Dawson; Schweizer, Edward; Uhlenhuth, Eberhard H.

In: Journal of Clinical Psychopharmacology, Vol. 17, No. 4, 08.1997, p. 247-254.

Research output: Contribution to journalArticle

Noyes, R, Moroz, G, Davidson, JRT, Liebowitz, MR, Davidson, A, Siegel, J, Bell, J, Cain, JW, Curlik, SM, Kent, TA, Bruce Lydiard, R, Mallinger, AG, Pollack, MH, Rapaport, M, Rasmussen, SA, Hedges, D, Schweizer, E & Uhlenhuth, EH 1997, 'Moclobemide in social phobia: A controlled dose-response trial', Journal of Clinical Psychopharmacology, vol. 17, no. 4, pp. 247-254. https://doi.org/10.1097/00004714-199708000-00002
Noyes R, Moroz G, Davidson JRT, Liebowitz MR, Davidson A, Siegel J et al. Moclobemide in social phobia: A controlled dose-response trial. Journal of Clinical Psychopharmacology. 1997 Aug;17(4):247-254. https://doi.org/10.1097/00004714-199708000-00002
Noyes, Russell ; Moroz, Georges ; Davidson, Jonathan R T ; Liebowitz, Michael R. ; Davidson, Arnold ; Siegel, Judith ; Bell, Jon ; Cain, John W. ; Curlik, Sharon M. ; Kent, Thomas A. ; Bruce Lydiard, R. ; Mallinger, Alan G. ; Pollack, Mark H. ; Rapaport, Mark ; Rasmussen, Steven A. ; Hedges, Dawson ; Schweizer, Edward ; Uhlenhuth, Eberhard H. / Moclobemide in social phobia : A controlled dose-response trial. In: Journal of Clinical Psychopharmacology. 1997 ; Vol. 17, No. 4. pp. 247-254.
@article{c4690d460593401da3238fedd7728342,
title = "Moclobemide in social phobia: A controlled dose-response trial",
abstract = "Although the monoamine oxidase inhibitor phenelzine has proven efficacious in social phobia, the risk of hypertensive crises has reduced its acceptability. The reversible monoamine oxidase inhibitor moclobemide has less potential for such reactions, but; its efficacy in this disorder remains unproven. A double-blind, placebo-controlled study was undertaken to assess the efficacy and safety of fixed doses of moclobemide. After a 1-week placebo run-in, subjects with social phobia were randomly assigned to placebo or one of five doses (75 mg, 150 mg, 300 mg, 600 mg, or 900 mg daily) of moclobemide for 12 weeks. Although a trend toward greater efficacy of higher doses of moclobemide was observed at 8 weeks, no differences in response to various doses of the drug and placebo were observed at 12 weeks. At 12 weeks, 35{\%} of subjects on 900 mg of moclobemide and 33{\%} of those on placebo were at least much improved. Moclobemide was well tolerated, insomnia being the only dose-related adverse event observed with the drug. In this dose-response trial, moclobemide did not demonstrate efficacy at; 12 weeks. Some other controlled studies have found moclobemide and brofaromine, another reversible monoamine oxidase inhibitor, efficacious in social phobia. Possible reasons for inconsistent findings are discussed.",
author = "Russell Noyes and Georges Moroz and Davidson, {Jonathan R T} and Liebowitz, {Michael R.} and Arnold Davidson and Judith Siegel and Jon Bell and Cain, {John W.} and Curlik, {Sharon M.} and Kent, {Thomas A.} and {Bruce Lydiard}, R. and Mallinger, {Alan G.} and Pollack, {Mark H.} and Mark Rapaport and Rasmussen, {Steven A.} and Dawson Hedges and Edward Schweizer and Uhlenhuth, {Eberhard H.}",
year = "1997",
month = "8",
doi = "10.1097/00004714-199708000-00002",
language = "English (US)",
volume = "17",
pages = "247--254",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Moclobemide in social phobia

T2 - A controlled dose-response trial

AU - Noyes, Russell

AU - Moroz, Georges

AU - Davidson, Jonathan R T

AU - Liebowitz, Michael R.

AU - Davidson, Arnold

AU - Siegel, Judith

AU - Bell, Jon

AU - Cain, John W.

AU - Curlik, Sharon M.

AU - Kent, Thomas A.

AU - Bruce Lydiard, R.

AU - Mallinger, Alan G.

AU - Pollack, Mark H.

AU - Rapaport, Mark

AU - Rasmussen, Steven A.

AU - Hedges, Dawson

AU - Schweizer, Edward

AU - Uhlenhuth, Eberhard H.

PY - 1997/8

Y1 - 1997/8

N2 - Although the monoamine oxidase inhibitor phenelzine has proven efficacious in social phobia, the risk of hypertensive crises has reduced its acceptability. The reversible monoamine oxidase inhibitor moclobemide has less potential for such reactions, but; its efficacy in this disorder remains unproven. A double-blind, placebo-controlled study was undertaken to assess the efficacy and safety of fixed doses of moclobemide. After a 1-week placebo run-in, subjects with social phobia were randomly assigned to placebo or one of five doses (75 mg, 150 mg, 300 mg, 600 mg, or 900 mg daily) of moclobemide for 12 weeks. Although a trend toward greater efficacy of higher doses of moclobemide was observed at 8 weeks, no differences in response to various doses of the drug and placebo were observed at 12 weeks. At 12 weeks, 35% of subjects on 900 mg of moclobemide and 33% of those on placebo were at least much improved. Moclobemide was well tolerated, insomnia being the only dose-related adverse event observed with the drug. In this dose-response trial, moclobemide did not demonstrate efficacy at; 12 weeks. Some other controlled studies have found moclobemide and brofaromine, another reversible monoamine oxidase inhibitor, efficacious in social phobia. Possible reasons for inconsistent findings are discussed.

AB - Although the monoamine oxidase inhibitor phenelzine has proven efficacious in social phobia, the risk of hypertensive crises has reduced its acceptability. The reversible monoamine oxidase inhibitor moclobemide has less potential for such reactions, but; its efficacy in this disorder remains unproven. A double-blind, placebo-controlled study was undertaken to assess the efficacy and safety of fixed doses of moclobemide. After a 1-week placebo run-in, subjects with social phobia were randomly assigned to placebo or one of five doses (75 mg, 150 mg, 300 mg, 600 mg, or 900 mg daily) of moclobemide for 12 weeks. Although a trend toward greater efficacy of higher doses of moclobemide was observed at 8 weeks, no differences in response to various doses of the drug and placebo were observed at 12 weeks. At 12 weeks, 35% of subjects on 900 mg of moclobemide and 33% of those on placebo were at least much improved. Moclobemide was well tolerated, insomnia being the only dose-related adverse event observed with the drug. In this dose-response trial, moclobemide did not demonstrate efficacy at; 12 weeks. Some other controlled studies have found moclobemide and brofaromine, another reversible monoamine oxidase inhibitor, efficacious in social phobia. Possible reasons for inconsistent findings are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0343683384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343683384&partnerID=8YFLogxK

U2 - 10.1097/00004714-199708000-00002

DO - 10.1097/00004714-199708000-00002

M3 - Article

C2 - 9241002

AN - SCOPUS:0343683384

VL - 17

SP - 247

EP - 254

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -